<DOC>
	<DOCNO>NCT01297348</DOCNO>
	<brief_summary>Lybrel® oral contraceptive delivers low dos levonorgestrel ethinyl estradiol ( 90 μg/20 μg ) . Lybrel take continuous basis without placebo pill-free interval inhibit menstrual cycle bleed deliver steady level 2 hormone long drug use . Lybrel market US July 2007 . The objective database case-control study estimate risk idiopathic VTE ( deep vein thrombosis pulmonary embolism ) current user Lybrel ( ethinyl estradiol 20ug/levonorgestrel 90ug ) compare current user oral contraceptive contain 20μg ethinyl estradiol .</brief_summary>
	<brief_title>Study Of Lybrel In Relation To Venous Thromboembolism</brief_title>
	<detailed_description>The base population consist currently available data current user ( 15-49 year old ) Lybrel oral contraceptive ( OC ) contain 20 µg ethinyl estradiol PharMetrics/IMS MarketScan database . From among base population , databases searched diagnosis deep vein thrombosis ( DVT ) , pulmonary embolism ( PE ) , cerebral venous sinus thrombosis ( CVST ) [ refer collectively venous thromboembolism VTE ] occur receipt Lybrel oral contraceptive contain 20 µg ethinyl estradiol . The intent include newly diagnose case VTE .</detailed_description>
	<mesh_term>Thrombosis</mesh_term>
	<mesh_term>Thromboembolism</mesh_term>
	<mesh_term>Embolism</mesh_term>
	<mesh_term>Venous Thromboembolism</mesh_term>
	<mesh_term>Pulmonary Embolism</mesh_term>
	<mesh_term>Venous Thrombosis</mesh_term>
	<mesh_term>Sinus Thrombosis , Intracranial</mesh_term>
	<mesh_term>Intracranial Thrombosis</mesh_term>
	<mesh_term>Ethinyl Estradiol</mesh_term>
	<mesh_term>Estradiol</mesh_term>
	<mesh_term>Polyestradiol phosphate</mesh_term>
	<mesh_term>Contraceptives , Oral</mesh_term>
	<mesh_term>Levonorgestrel</mesh_term>
	<mesh_term>Ethinyl estradiol , levonorgestrel drug combination</mesh_term>
	<mesh_term>Estradiol 17 beta-cypionate</mesh_term>
	<mesh_term>Estradiol 3-benzoate</mesh_term>
	<mesh_term>Estradiol valerate</mesh_term>
	<mesh_term>Contraceptive Agents</mesh_term>
	<criteria>New user study drug ( i.e. , Lybrel comparison OCs ) No specific exclusion criterion base study cohort .</criteria>
	<gender>Female</gender>
	<minimum_age>15 Years</minimum_age>
	<maximum_age>49 Years</maximum_age>
	<verification_date>June 2013</verification_date>
	<keyword>Lybrel</keyword>
	<keyword>levonorgestrel</keyword>
	<keyword>ethinyl estradiol</keyword>
	<keyword>venus thromboembolism ( VTE )</keyword>
	<keyword>oral contraceptive ( OC )</keyword>
	<keyword>safety</keyword>
	<keyword>database study</keyword>
	<keyword>case-control study</keyword>
</DOC>